Treatment of schizophrenic patients - Recurrence rate falls with long-acting risperidone

被引：0
|
作者：
Oetzel, S
机构：
来源：
NERVENHEILKUNDE | 2004年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：87 / 87
页数：1
相关论文
共 50 条
  • [41] Long-term benefits of treatment with risperidone long-acting injection (LAI) in patients with schizophrenia
    Turner, M
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 71 - 71
  • [42] QoL, global functioning and social adaptation of schizophrenic subjects treated with long-acting risperidone
    Golubovic, S. Tosic
    Sibinovic, V. S.
    Slavkovic, V. S.
    Zikic, Z. O.
    Gugleta, D. C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S494 - S494
  • [43] Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
    Somaia Mohamed
    Robert Rosenheck
    Ilan Harpaz-Rotem
    Douglas Leslie
    Michael J. Sernyak
    Psychiatric Quarterly, 2009, 80 : 241 - 249
  • [44] Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
    Mohamed, Somaia
    Rosenheck, Robert
    Harpaz-Rotem, Ilan
    Leslie, Douglas
    Sernyak, Michael J.
    PSYCHIATRIC QUARTERLY, 2009, 80 (04) : 241 - 249
  • [45] Long-acting risperidone:: Focus on safety
    Mueller, Hans-Juergen
    CLINICAL THERAPEUTICS, 2006, 28 (05) : 633 - 651
  • [46] Switching schizophrenic patients from conventional depot neuroleptics to long-acting injectable risperidone reduces extrapyramidal symptoms
    Medori, R
    Schreiner, A
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S401 - S401
  • [47] Long-acting risperidone in schizophrenic patients compared with oral olanzapine and haloperidol decanoate:: A cost-effectiveness analysis
    Llorca, PM
    Mosqueda, JGJ
    Miadi-Fargier, H
    Durand-Zaleski, I
    Lançon, C
    Casadebaig, F
    Philippe, A
    Guillon, P
    Mehnert, A
    Chicoye, A
    VALUE IN HEALTH, 2002, 5 (06) : 456 - 456
  • [48] Risperidone long-acting formulation in treatment-resistant schizophrenic patients the predictive value of plasma levels in relation to clinical response and safety
    Cerveri, G.
    Volonteri, L. S.
    De Gasperi, I.
    Papini, B.
    Papa, P.
    Mauri, M. C.
    Mencacci, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S524 - S524
  • [49] Risperidone long-acting injection in the treatment of recently versus longer diagnosed patients with schizophrenia
    Lambert, T.
    Olivares, J. M.
    Tuma, I.
    Peuskens, J.
    Pecenak, J.
    bij de Weg, H.
    Eriksson, L.
    Bork, B.
    Povey, M.
    Zhao, Z.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S434 - S434
  • [50] Risperidone long-acting injectable in patients with a new diagnosis of psychosis
    Parellada, E
    Chrzanowski, W
    Andrezina, R
    Milanova, V
    Glue, P
    Medori, R
    Masiak, M
    EUROPEAN PSYCHIATRY, 2005, 20 : S75 - S76
12345